How We Can Support the Drug Development Pipeline

Mutation Analysis

Advances in human genome technology has contributed to the development of personalized medicine, where molecular profiles of patients are examined for mutations by analysis of DNA/RNA. These SNP mutations and other DNA variations affect response to treatment therapies. Mutation analysis of patient populations also enriches clinical trial studies providing meaningful data and decreasing costs associated with poor compliance or toxic effects.

Source BioScience provides its clients with an expertise in genotyping analysis and patient enrichment studies. Using a range of platforms and kits in its GLP, GCP accredited laboratory facilities, Source BioScience can provide support for R & D studies, through to clinical trials and FDA submissions.

Some examples of drugs for which we can supply genotyping analysis are given in the list below:

• CYP2D6 - importance of genetic variability in product label for Tamoxifen.
• CYP2C19 - importance of genetic variability in product label for Omeprazole.
• Roche AmpliChip (CYP2D6/CYP2C19).
• NAT2 acetylation.
• VKORC1- importance of genetic variability in product label for Warfarin/Acenocoumarol.
• UGT1A1- importance of genetic variability in product label for Irinotecan/Camptosar.

For further information on our genotyping capabilities for these drugs and other therapeutic indications please contact us at pharma.

Mutation analysis for molecular biomarkers

Source BioScience is a central reference lab for a range of molecular biomarkers including:

• KRAS
• EGFR
• BRAF
• PI3K
• JAK
• Her2

SourceBioScience is a reference lab for HER2 FISH and IHC testing offering full pathology review if required. For further information please contact us at pharma .